Estradiol and raloxifene as adjunctive treatment for women with schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials.
Zijia LiYucheng WangZhe WangLingtao KongLinzi LiuLiu LiYanqing TangPublished in: Acta psychiatrica Scandinavica (2022)
Our meta-analysis showed that estradiol and raloxifene are effective and safe adjunctive treatments that improve schizophrenia symptoms in women. Moreover, the effects of estradiol and raloxifene differed in terms of timing and dosage. Both are promising adjunctive treatments that merit further study.
Keyphrases
- placebo controlled
- double blind
- bipolar disorder
- phase iii
- systematic review
- clinical trial
- phase ii
- estrogen receptor
- phase ii study
- study protocol
- polycystic ovary syndrome
- meta analyses
- open label
- type diabetes
- pregnancy outcomes
- pregnant women
- squamous cell carcinoma
- skeletal muscle
- case control
- cervical cancer screening
- replacement therapy